Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors
Description:
The latest research has found that the use of positron-labeled FAP inhibitors for targeting FAP has achieved very good results in displaying tumor stroma, especially for tumors with poor FDG PET/CT observation, such as liver cancer, renal cancer, and gastric cancer. Although the studies were based on small sample data or case reports, they achieved significantly better results than 18F-FDG [13,15-17].
Contacts:
En-Tao Liu, M.Dliuentao@gdph.org.cn
+86 15818806018
Lei Jiang, M.D (Principal Investigator)jianglei6814@gdph.org.cn
+86 20 8352 5975
Government Study Link:
NCT06182644 - Click here to see study onClinicalTrials.gov
